|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EVI5 |
Gene summary for EVI5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EVI5 | Gene ID | 7813 |
| Gene name | ecotropic viral integration site 5 | |
| Gene Alias | EVI-5 | |
| Cytomap | 1p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O60447 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7813 | EVI5 | CCI_1 | Human | Cervix | CC | 6.51e-04 | 8.29e-01 | 0.528 |
| 7813 | EVI5 | CCI_2 | Human | Cervix | CC | 4.60e-02 | 5.70e-01 | 0.5249 |
| 7813 | EVI5 | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.98e-22 | -6.49e-01 | 0.0155 |
| 7813 | EVI5 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.97e-02 | -5.03e-01 | -0.1207 |
| 7813 | EVI5 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.64e-07 | -2.41e-01 | -0.1526 |
| 7813 | EVI5 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.18e-02 | -2.54e-01 | -0.1464 |
| 7813 | EVI5 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.40e-04 | -4.57e-01 | -0.2061 |
| 7813 | EVI5 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.45e-02 | -6.02e-01 | -0.1462 |
| 7813 | EVI5 | HTA11_9341_2000001011 | Human | Colorectum | SER | 9.63e-04 | -6.55e-01 | -0.00410000000000005 |
| 7813 | EVI5 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.27e-10 | -6.16e-01 | 0.096 |
| 7813 | EVI5 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.02e-07 | -7.47e-01 | 0.0528 |
| 7813 | EVI5 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.52e-05 | -4.90e-01 | 0.0338 |
| 7813 | EVI5 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.84e-08 | -4.78e-01 | 0.0674 |
| 7813 | EVI5 | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.17e-04 | -4.44e-01 | 0.0588 |
| 7813 | EVI5 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.97e-27 | -5.72e-01 | 0.294 |
| 7813 | EVI5 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.37e-03 | -3.32e-01 | 0.3859 |
| 7813 | EVI5 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 9.37e-10 | -6.94e-01 | 0.2585 |
| 7813 | EVI5 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.72e-26 | -6.80e-01 | 0.3005 |
| 7813 | EVI5 | A001-C-207 | Human | Colorectum | FAP | 2.56e-05 | -3.73e-01 | 0.1278 |
| 7813 | EVI5 | A015-C-203 | Human | Colorectum | FAP | 4.82e-33 | -5.30e-01 | -0.1294 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
| GO:00435476 | Cervix | CC | positive regulation of GTPase activity | 53/2311 | 255/18723 | 8.72e-05 | 1.16e-03 | 53 |
| GO:00161977 | Cervix | CC | endosomal transport | 48/2311 | 230/18723 | 1.65e-04 | 1.97e-03 | 48 |
| GO:00164827 | Cervix | CC | cytosolic transport | 33/2311 | 168/18723 | 4.43e-03 | 2.70e-02 | 33 |
| GO:0016197 | Colorectum | AD | endosomal transport | 90/3918 | 230/18723 | 1.88e-10 | 1.73e-08 | 90 |
| GO:0016482 | Colorectum | AD | cytosolic transport | 68/3918 | 168/18723 | 6.00e-09 | 3.72e-07 | 68 |
| GO:0043087 | Colorectum | AD | regulation of GTPase activity | 110/3918 | 348/18723 | 1.64e-06 | 5.03e-05 | 110 |
| GO:0042147 | Colorectum | AD | retrograde transport, endosome to Golgi | 37/3918 | 91/18723 | 1.46e-05 | 3.14e-04 | 37 |
| GO:0043547 | Colorectum | AD | positive regulation of GTPase activity | 75/3918 | 255/18723 | 7.95e-04 | 7.91e-03 | 75 |
| GO:00161971 | Colorectum | SER | endosomal transport | 61/2897 | 230/18723 | 1.03e-05 | 3.35e-04 | 61 |
| GO:00164821 | Colorectum | SER | cytosolic transport | 46/2897 | 168/18723 | 5.20e-05 | 1.25e-03 | 46 |
| GO:00430871 | Colorectum | SER | regulation of GTPase activity | 77/2897 | 348/18723 | 5.90e-04 | 8.07e-03 | 77 |
| GO:00161972 | Colorectum | MSS | endosomal transport | 79/3467 | 230/18723 | 7.04e-09 | 4.39e-07 | 79 |
| GO:00164822 | Colorectum | MSS | cytosolic transport | 59/3467 | 168/18723 | 2.29e-07 | 9.79e-06 | 59 |
| GO:00430872 | Colorectum | MSS | regulation of GTPase activity | 101/3467 | 348/18723 | 1.00e-06 | 3.46e-05 | 101 |
| GO:00421471 | Colorectum | MSS | retrograde transport, endosome to Golgi | 33/3467 | 91/18723 | 4.78e-05 | 8.71e-04 | 33 |
| GO:00435471 | Colorectum | MSS | positive regulation of GTPase activity | 68/3467 | 255/18723 | 7.97e-04 | 8.38e-03 | 68 |
| GO:00430873 | Colorectum | FAP | regulation of GTPase activity | 85/2622 | 348/18723 | 1.20e-07 | 7.68e-06 | 85 |
| GO:00164823 | Colorectum | FAP | cytosolic transport | 47/2622 | 168/18723 | 1.58e-06 | 6.72e-05 | 47 |
| GO:00435472 | Colorectum | FAP | positive regulation of GTPase activity | 61/2622 | 255/18723 | 1.39e-05 | 3.73e-04 | 61 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EVI5 | SNV | Missense_Mutation | c.663N>G | p.Ser221Arg | p.S221R | O60447 | protein_coding | tolerated(0.06) | probably_damaging(0.962) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| EVI5 | SNV | Missense_Mutation | novel | c.1155N>A | p.His385Gln | p.H385Q | O60447 | protein_coding | tolerated(0.2) | probably_damaging(0.948) | TCGA-AC-A2BK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| EVI5 | SNV | Missense_Mutation | c.365C>T | p.Ser122Leu | p.S122L | O60447 | protein_coding | deleterious(0.02) | probably_damaging(0.945) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| EVI5 | insertion | Frame_Shift_Ins | novel | c.2416_2417insTGCGTGTCACAGCAACACTCTGTCTCAA | p.Gln806LeufsTer32 | p.Q806Lfs*32 | O60447 | protein_coding | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| EVI5 | insertion | Nonsense_Mutation | novel | c.1736_1737insATCCCTGGCCTCTACCCACTAGATGCCAGTAACGGCTCTCCTACCT | p.Ile580SerfsTer7 | p.I580Sfs*7 | O60447 | protein_coding | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| EVI5 | deletion | Frame_Shift_Del | novel | c.902delA | p.His301LeufsTer25 | p.H301Lfs*25 | O60447 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| EVI5 | SNV | Missense_Mutation | rs771345036 | c.2003G>A | p.Ser668Asn | p.S668N | O60447 | protein_coding | tolerated(0.27) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EVI5 | SNV | Missense_Mutation | novel | c.1425G>T | p.Glu475Asp | p.E475D | O60447 | protein_coding | deleterious(0.03) | possibly_damaging(0.669) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EVI5 | SNV | Missense_Mutation | novel | c.675G>T | p.Glu225Asp | p.E225D | O60447 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EVI5 | SNV | Missense_Mutation | c.2441G>C | p.Arg814Thr | p.R814T | O60447 | protein_coding | tolerated_low_confidence(0.6) | benign(0.017) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |